The phase I/II trial aimed to present updated results on long-term efficacy and safety of S+T and EP regimen for SCLC patients. The primary endpoints were RP2D of S and PFS. The results showed promising efficacy and tolerable toxicity in 1L advanced SCLC, potentially offering a novel therapeutic option, particularly for patients without […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Objectives: Disparities exist in the length and quality of survival from melanoma. This study evaluated, in a Texas cohort, patient factors associated with melanoma survival and examined if newer immune-oncologic agents extend survival compared with …
Objectives: Melanoma survival has greatly improved with the advent of immunotherapy, but unequal access to these medications may exist due to nonmedical patient factors such as insurance status, educational background, and geographic proximity to treatment. Methods: …
Objectives: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) promising in treating metastatic HER2+ and HER2-low breast cancer. This updated systematic review and meta-analysis, integrating data from the latest clinical trials, aimed to evaluate …
